Objective. Cellular immune responses are difficul to detect in the peripheral blood of persons with chronic hepatitis C virus (HCV) infection. We sought to determine whether T cell responses were present in the liver of patients with human immunodeficienc virus (HIV) and HCV coinfection.
1 ϫ 10 singly infected with HCV (7/8; median, 647 sfc/ cells). Intrahepatic HCV-specifi CD4 + cell responses were 6 1 ϫ 10 also comparable in both groups and correlated with the intrahepatic CD8 + cell responses ( ; ). r p 0.59 P p .03
Conclusion. HCV-specifi CD8
+ cell responses are present in the liver of persons with chronic HCV infection even when they are coinfected with HIV; these correlate with intrahepatic HCV-specifi CD4 + cell responses.
Because of the shared routes of transmission, coinfection with hepatitis C virus (HCV) and HIV is common and is of increasing clinical relevance [1] [2] [3] . Coinfection with HIV leads to an increased risk of chronic HCV infection [4] , increased HCV loads [5, 6] , and an increased risk of progression to cirrhosis [7] . This increased risk of progression to cirrhosis is correlated with the degree of immunodeficiency-th fib osis progression rate is highest in those individuals with a CD4 + cell count of !200 cells/mm 3 [8] , and the progression of liver disease may slow with immune reconstitution after the administration of antiretroviral therapy (ART) [9, 10] .
Vigorous and polyclonal immune responses are clearly important in the spontaneous recovery from acute HCV infection [11] [12] [13] [14] and probably play an important role in clearance after interferon (IFN) and ribavirin therapy [15, 16] . However, the role of the immune response in the progression of liver injury during HCV infection is, at present, controversial. Although clinical evidence in persons who are coinfected with HIV and HCV and those with other immunodeficiencies all of whom have more rapid disease progression, suggests that cellular immune responses play a role in limiting liver injury, the classic understanding of the pathogenesis of liver disease caused by HCV infection is that it is mediated by the cellular immune response [17] [18] [19] . Model systems that have used the constitutive expression of HCV in transgenic animals have suggested that HCV proteins are not directly cytopathic [20, 21] and have demonstrated an absence of liver injury in the absence of a host immune response against the virus [22] , with liver injury becoming apparent only after the adoptive transfer of HCV-specifi cells into the animals [23] . In individuals with chronic HCV infection, HCV-specifi CD4
+ and CD8 + cell responses in the peripheral blood are weak and barely detectable, even by sensitive tests, such as those based on tetramers [24, 25] . However, numerous studies have shown that HCV-specifi CD4
+ and CD8 + cell responses are present in the liver in chronic HCV infection at much higher frequency than in the peripheral blood [26] [27] [28] [29] [30] . To date, a limited number of studies have examined the HCV-specifi immune response in the setting of coinfection. HCV-specifi responses are detectable only in the periphery in HIV-infected long-term nonprogressors [31, 32] ; in those with progressive HIV infection, even when they are receiving ART, responses in the peripheral blood are of very low magnitude and of much lower frequency than HIV-specifi responses [33] . We have recently characterized intrahepatic cytokine production by HCV-specifi CD4 + cells in the setting of coinfection [34] , but, to our knowledge, there are no data available on intrahepatic CD8 + cell responses. In the present study, we sought to determine whether HCVspecifi CD8
+ cell responses were present in the liver of coinfected persons and whether there were qualitative differences in the intrahepatic CD4
+ and CD8 + cell responses, compared with those in patients infected with HCV alone.
PATIENTS, MATERIALS, AND METHODS

Patients and samples.
Liver and blood samples were obtained from 18 patients with chronic HCV infection who were undergoing routine liver biopsies for diagnostic purposes before receiving anti-HCV treatment. Eight patients were singly infected with HCV, and 10 patients were coinfected with HCV and HIV (table 1). All patients were HCV RNA positive, and none had evidence of clinical liver decompensation, including ascites, encephalopathy, jaundice, bleeding varices, or coagulopathy (prothrombin time, 13 s over control). Persons with other forms of liver disease-including hepatitis B virus (HBV) infection and alcoholism-and other immunosuppressive conditions-including malignancy, chronic renal failure requiring hemodialysis, organ transplant, and other comorbid diseases requiring immunosuppressive therapy-were excluded. The protocol was reviewed by the investigational review boards of the University of Cincinnati College of Medicine and the Beth Israel Deaconess Medical Center, and all patients gave informed consent for the collection of samples.
Vaccinia-HCV recombinant viruses, recombinant HCV proteins, and a control peptide pool. Vaccinia constructs (vv), which were used for the CD8 assays, were provided by Michael Houghton (Chiron) and Charles Rice (Rockefeller University, New York, NY). Six vaccinia-HCV recombinant viruses were constructed to express the HCV proteins spanning the entire HCV-1a genome: vv-core/E1 (aa 1-339), vv-E1(NS1)/NS2 (aa 347-906), vv-E2/NS2/NS3 (aa 364-1619), vv-NS4 (aa 1590-2050), vv-NS5A (aa 2005-2396), and vv-NS5B (aa 2396-3011). A vv expressing only Escherichia coli b-galactosidase gene (vvlac) was used as a control. As a control to assess immune responses against recall antigens, the CD8 + cell responses to other viruses were evaluated by use of a pool of 23 major histocompatibility class I-restricted T cell epitopes from human cytomegalovirus (CMV), Epstein Barr virus (EBV), and influenz virus (CEF; AIDS Reagent Program, National Institutes of Health [NIH] ). The recombinant HCV proteins used for the CD4 assays were derived from HCV genotype 1b and included core (aa 1-115) and nonstructural (NS) proteins NS3 (aa 1007-1534) and NS5 (aa 2622-2868; Mikrogen).
Preparation of peripheral blood mononuclear cells (PBMCs) and liver-infiltratin lymphocytes. Liver-tissue samples were cut into 2 parts, and each part was cultured in 1 well of a 24-well plate in R-10-100 or R-10 medium (RPMI 1640 medium plus 10% heat-inactivated fetal calf serum, antibiotics, and HEPES buffer) supplemented with 100 IU/mL of recombinant interleukin-2 (AIDS Reagent Program, NIH). Bispecifi monoclonal antibodies (MAbs) CD3,4B or CD3,8 (gift from Johnson Wong, Massachusetts General Hospital, Boston) were added to each well at 0.5 mg/mL, to nonspecificall expand the intrahepatic CD8-or CD4-enriched populations, respectively [26, 34] . When cells reached confluenc (density, 2-3 million cells/ mL), they were subcultured in the presence of a 4:1 ratio of feeder cells (allogeneic PBMCs irradiated with 3000 rad) in medium with 0.1 mg/mL of anti-CD3 MAb (gift from Johnson Wong, Massachusetts General Hospital, Boston) as a polyclonal stimulus of T cell proliferation. At no time during the expansion process were liver-infiltratin lymphocytes exposed to exogenous HCV antigens. Cells were cultured for ∼5-6 weeks, then cryopreserved for further assays. PBMCs were isolated from blood by Ficoll-Hypaque (Amersham Bioscience) density-gradient centrifugation and were cryopreserved. These PBMCs were used to prepare the autologous antigen-presenting cells. For the CD8 assays, EBV-transformed B cell lines were established, as described elsewhere [26] .
IFN-g enzyme-linked immunospot (ELISpot) assays. For ELISpot assays, 96-well polyvinylidene difluorid plates (Millipore) were precoated with 100 mL of primary MAb anti-IFNg (Endogen) at a concentration of 5 mg/mL in 1ϫ PBS and incubated overnight at 4ЊC. Excess antibody was removed by 3 successive washes with PBS. Remaining binding sites on the wells were then saturated with R-10 for 30 min at 37ЊC. Enriched lymphocytes were plated in triplicate at cells/ 5 0.5 ϫ 10 well. The CD8-enriched liver-infiltratin lymphocytes were cocultured for 20 h with an equal number of autologous EBVtransformed B cell lines that had been infected for 1 h at 37ЊC with recombinant vaccinia-HCV vectors at an MOI of 5 pfu/ cell or in presence of the CEF peptide pool (2 mg/mL). The CD4-enriched liver-infiltratin lymphocytes were cocultured for 48 h with an equal number of irradiated (3000 rads) autologous PBMCs in the presence of the recombinant HCV proteins (1 mg/mL). Positive control wells consisted of phytohemagglutinin (5 mg/mL; Sigma). Negative control wells consisted of EBV-transformed B cell lines alone or infected with vv-lac for the CD8 assays and buffer alone for the CD4 assays. After 20 h for the CD8 assays and 48 h for the CD4 assays, cells were removed by successive washes: 3 times with PBS, 3 times with PBS that contained 0.05% Tween 20, and 3 times with PBS. Then, 50 mL of biotin-conjugated secondary MAb anti-human IFN-g (Endogen) was added to each well at a concentration of 0.2 mg/mL and incubated for 2 h at 37ЊC. The plates were rinsed 3 times with PBS; then, 100 mL of streptavidin alkaline phosphatase (1:1000 dilution; Sigma) was added for 1 h at 37ЊC. Plates were washed 3 times with PBS, then 50 mL of substrate (5-bromo-4-chloro-indolyl-phosphate/4-nitrobluetetrazolium liquid; Sigma) was added and incubated at room temperature until the appearance of blue spots, at which point they were rinsed with tap water. Antigen-specifi spot-forming cell frequencies were measured on an automated microscope (Zeiss) and are expressed as values obtained after background subtraction. For the experiments with vaccinia, this background consisted of results observed with EBV-transformed B cell lines infected with lac. For the analysis of the CD8 + cell response to CEF, the background consisted of EBV-transformed B cell lines alone. For the CD4 assays, the background was the result observed with buffer alone.
Overall results were considered to be positive if a minimum of 50 sfc/ cells were detected above background. This 6 1 ϫ 10 positive threshold was arbitrarily define according to the positive threshold used for the HIV ELISpot experiments in peripheral blood [35] and is 13 SDs above any response observed in the peripheral blood of healthy donors or in the liver of 1 HCV-negative patient with HBV infection (data not shown), because it is not possible to obtain fresh, healthy human liver for comparison. Statistical analysis. The coinfected and HCV singly infected groups were compared by use of the Mann-Whitney U test for continuous data and Fisher's exact test for categorical data. Spearman rank tests were performed for the correlations. Calculations were performed by use of STATview SAS PC software (version 6.01; SAS Institute), and was considered P р .05 to be significant
RESULTS
Patient characteristics.
Patient characteristics at the time of study entry are shown in table 1. All the coinfected patients were treated for HIV, and most had undetectable HIV loads (median, !50 copies/mL; range, !50-74,073 copies/mL). CD4 + cell counts from the time of the liver biopsy were done only for the coinfected group and were relatively high in this cohort (median, 456 cells/mm + cell percentages according to FACS analysis were 77% in both the HIV-HCV coinfected and HCV singly infected groups (data not shown). We studied the intrahepatic CD4 + cell responses to 3 HCV antigens, including the core and NS3 and NS5, using autologous irradiated PBMCs as antigen-presenting cells. One-half of the patients in each group responded (150 sfc/ ) to at least 1 HCV antigen. As with the CD8 + cell re- 6 1 ϫ 10 sponses, the CD4 + cells producing IFN-g in response to each 1 of the 3 studied HCV proteins were detected with highly variable + cell responses. Given that the activity of CD8 + cells is based on CD4 + cells, we sought to determine whether there was a relationship between these 2 populations. Interestingly, Figure 4 . Correlation between total intrahepatic hepatitis C virus (HCV)-specific CD8
+ and CD4 + cell responses in 8 HIV-HCV coinfected and 6 HCV singly infected patients. Total HCV-specific CD8
+ and CD4 + cell responses were measured by use of an interferon (IFN)-g enzyme-linked immunospot (ELISpot) assay, as described in Patients, Materials, and Methods. Correlation was assessed between the total HCV-specific intrahepatic CD8
+ and CD4 + responses in all patients by use of Spearman's rank test. There was a significant positive correlation between CD8 + and CD4 + cell responses. sfc, spot-forming cells.
overall total numbers of HCV-specifi intrahepatic CD8 + cells were positively correlated with the total number of HCV-specifi intrahepatic CD4 + Th1 cells ( ; ) (figu e r p 0.596 P p .034 4), but neither HCV-specifi intrahepatic CD8
+ nor CD4 + cell responses were correlated with the peripheral CD4 + cell counts ( ; ) in persons with HIV-HCV coinfection (data r p Ϫ0.1 P 1 .8 not shown). No correlations were found either with the intrahepatic IFN-g HCV-specifi CD8
+ or CD4 + cell responses and plasma HCV loads or liver disease (histology or liver enzymes) in this small cohort.
DISCUSSION
In the present study, our objective was to determine whether there were qualitative differences in the intrahepatic T cell response between patients with HIV-HCV coinfection and those infected with HCV alone. We measured the HCV-specifi T cell response in liver lymphocytes using a modifie IFN-g ELISpot assay to detect CD8 + cell responses against the entire HCV genome and CD4 + cell responses against 3 recombinant HCV proteins-core, NS3, and NS5. We found that HCVspecifi CD8
+ and CD4 + cell responses were present and recognized multiple antigens in the liver of patients with HCV-HIV coinfection. We then compared the intrahepatic T cell responses between the HCV-HIV coinfected and HCV singly infected patients. Despite the presence of HIV, there was no difference in the HCV-specifi CD8 + or CD4 + cell response in our cohort. Therefore, we have confi med that HCV-specifi responses are not absent in HCV-HIV coinfection but, rather, appear to compartmentalize to the liver, as they do in HCV infection alone. Although we did not specificall compare the response in the liver and peripheral blood in the present study, we and others have previously demonstrated an attenuated response in the peripheral blood of coinfected patients [34, 36, 37] . Moreover, we found a positive correlation between the HCV-specifi CD4 + Th1 cell responses and the CD8 + cell responses but not with the peripheral CD4 + cell counts. One of the limitations of measuring T cell responses in the liver is the low number of cells obtained in clinically achievable amounts of liver tissue, which required us to expand cells. We believe that our expansion method does not prime naive T cells, given that we were unable to expand HCV-reactive cells from the peripheral blood of patients naive for HCV or from the liver of 1 patient who was HCV negative but had HBV infection. Because of limitations on the numbers of cells that can be directly isolated from liver tissue, a comparison of T cell responses before and after the expansion of intrahepatic cells was not possible. However, we previously expanded CD4 + cells from PBMCs and found that HCV-specifi CD4 + cell responses were quantitatively expanded, as would be expected for the CD4-enriched PBMCs, and there were no significan qualitative differences in antigenic specificit before and after expansion [34] . The findin that responses against a pool of recall antigens was higher in the coinfected patients was a surprise, and we speculate that this higher frequency is due to a number of factors related to HIV itself or the care of HIV, such as more frequent CMV viremia or better rates of immunization against influenza either of which could have contributed to the higher response against this pool of peptides. It is possible that some aspect of CD8 + cells in HIV allows for the easier expansion of CEF-reactive cells, although this is less likely, because the intrahepatic CD8 + cell responses to EBV-transformed B cells alone that reflecte the responses to EBV (one of the CEF components) were similar in the 2 groups of patients.
In the present cohort, the presence of HIV-related immunodeficienc had no effect on HCV-specifi immune responses. However, all coinfected patients in our study were receiving ART; as a consequence, most of them had undetectable HIV loads and relatively high, although not normal, CD4 + cell counts. In this limited study, we cannot address the issue of whether the same results would be found in persons with profound immunodeficienc (CD4 + cell counts !200 cells/mm 3 ). One of the difficultie with this particular type of study is that patients with more profound immunodeficienc are often not considered to be appropriate candidates for the treatment of HCV and do not routinely undergo liver biopsy. However, as more data on treatment response rates in patients with coinfection become available and as HIV providers realize the importance of liver biopsies in the determination of the stage of liver disease, we hope to extend these studies to patients with more severe immunodeficienc .
An interesting findin here is that HCV-specifi CD8 + cell responses in the liver were positively correlated with intrahepatic CD4 + Th1 cell responses to HCV but not to the peripheral CD4 + cell count, which is consistent with the finding of a report that described the same correlation in the peripheral blood of HIV-infected long-term nonprogressors who were coinfected with HCV [31] . Together, this emphasizes the importance of Th1 responses in the maintenance of CD8 + cell activity in chronic HCV infection. Studies in chimpanzee models have indicated that HCV replication is prolonged in the absence of intrahepatic memory CD8 + cells [38] and that the capacity of the CD8 + cells to terminate infection is limited in the absence of adequate CD4 + cell help [39] . In HIV monoinfection, a positive association between HIV-specifi CD8 + and CD4 + Th1 cell responses that inversely correlated with HIV loads has been described in untreated HIV-infected patients [40] as well as in patients receiving ART, who, despite detectable HIV viremia, maintained persistently low HIV loads and stable CD4 + cell counts ( [41] ). Of note, no correlation between the HIV-specifi CD8 + cell responses and the peripheral CD4 + cell counts has been observed in ART-treated patients who have persistently low viral loads (N.A. et al., unpublished data). This lack of correlation with the CD4 + cell counts has also been described in untreated HIV-infected patients monitored before the advent of highly active ART [42] , which suggests that CD4 + cell depletion does not directly influenc the loss of virus-specifi CD8 + cell responses.
One of the interesting questions raised by the present and other studies that suggest the compartmentalization of immune responses to the liver during chronic infection is why this should happen. One simple explanation might be that the major site of HCV replication is within hepatocytes, so the virusspecifi cells are homing to the major site of antigen. However, HCV might also specificall up-regulate chemokines or their receptors that are involved in the homing of activated T cells to areas of inflammatio [43] . For example, IFN-g-inducible protein-10, a chemokine that recruits activated T cells, has recently been shown by in situ hybridization to be expressed in the liver during chronic HCV infection, with a concomitant increase of the ligand CXCR3 on infiltratin liver lymphocytes [44] . Similarly, the expression of HCV may specificall drive the expression of the CC chemokines RANTES and monocyte chemotactic protein-1 [45] . Other groups have reported high expression of both CXC and CC chemokines in activated T cells within the liver during HCV infection and the correlation of these markers with severity of liver injury [46, 47] . Costimulatory molecule interactions such as CD28/B7, Fas/Fas-ligand, and CD40/CD154 may also play an important role in the pathogenesis of HCV infection. Whether the presence of HIV alters chemokine or costimulatory expression in the HCV-infected liver represents an interesting area of future study.
In summary, the present results demonstrate the presence of broadly directed HCV-specifi CD8 + cell responses in the liver of patients with chronic HCV infection, even in the presence of HIV coinfection, and suggest the importance of the CD4 + cell help for the maintenance of these CD8 + cell responses. Future studies will be needed to determine the role that these cells play in liver injury.
